Research!America board members Bill Hait, M.D., Janssen Research & Development, and Keith Yamamoto, Ph.D., University of California, San Francisco, will be discussing the concept of immorbidity—a perspective on medicine where priorities shift from treating or curing diseases like cancer and Alzheimer’s to preventing and delaying disease, at the BIO International Convention on Wednesday, June 8.
The session, Lifespan or Healthspan: Is it Time for a Paradigm Shift in the Life Sciences? An Interview with Bill Hait, Global Head, Janssen Research & Development, LLC, facilitated by Research!America, will take place during the convention, June 6-9 in San Francisco, CA. The session will be the opening event to the precision medicine track, one of the 18 session tracks offered during the convention.
The conversation between Dr. Hait and Dr. Yamamoto will focus on the science and policy rationale behind the concept of immorbidity, its roots in personalized medicine, its particular relevance to oncology and the case for a major shift in investment and effort within the life sciences enterprise away from post-symptom to pre-symptom care.
The BIO International Convention attracts over 15,000 biotechnology and industry leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. This event covers a variety of research areas, including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy. In addition to the wide variety of sessions, the convention will also have an Exhibition Hall, where many of Research!America’s alliance members will be exhibiting. For more information visit www.convention.bio.org.